Search

Displaying results 4131 - 4140 of 6835 in total
  1. Drug

    Fucoxanthin

    go.drugbank.com/drugs/DB15462
    Investigational

    , but the exact mechanism of anti-cancer action of fucoxanthin is not fully elucidated. … Fucoxanthin causes antitumor and anticarcinogenic effects by inducing G1 cell-cycle arrest and apoptosis by modulating expression of various cellular molecules and cellular signal transduction pathways

  2. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency. [L2917]

  3. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  4. Drug

    Hydroxyethyl ethylcellulose

    go.drugbank.com/drugs/DB14139
    Approved

    Hydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.

  5. Drug

    Lifileucel

    go.drugbank.com/drugs/DB17107
    ApprovedInvestigational

    ] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma. … Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341

  6. Drug

    BI 4060107

    go.drugbank.com/drugs/DB33963
    Experimental

    BI 4060107 is under investigation in clinical trial NCT07827144 (A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)).

  7. Drug

    Meclofenamic acid

    go.drugbank.com/drugs/DB00939
    ApprovedInvestigationalVet approved

    A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.

  8. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    [A3922] This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684] … Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.[L12684] It was first described in the literature in 2001.

  9. Drug

    Mesterolone

    go.drugbank.com/drugs/DB13587
    Investigational

    It is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen. … Mesterolone demonstrated to have minimal effect on sperm counts and levels of FSH or LH [A27177, A27178].

  10. Drug

    SYNB1353

    go.drugbank.com/drugs/DB17666
    Investigational

    It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983] … [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria.